Two typos have been found in text. The correct contents are shown below.
1. Page 2068, right column, 1st paragraph after the title - line number 24: 40 ± 3% needs to be changed to 75.67% ± 3% as follows “Combining MPL resulted in 35 ± 4% and 75.67 ± 3% decrease in the number of A2780 and OVCAR-3 colonies recovering from doxorubicin (P<0.001)”.
2. Page 2072, right column, 1st paragraph, 1st line: 40% should be changed to 75.67% as follows “MPL with PLD resulted in 35% and 75.67% colony reduction in A2780 and OVCAR-3 cells, respectively”.
In addition, an error has been found that there was a repetition of a photo in Figure 2. Therefore, we provide the correct version to displace the wrong figures and reflect changes. We sincerely apologize for our oversight and any confusion it may have caused. The corrected Figure 2 is shown below.
Figure 2.
Co-treatment of MPL with doxorubicin/gemcitabine inhibits the formation of ovarian cancer cell colonies. A2780 and OVCAR-3 cells were seeded at a low density in the presence of MPL, either alone or together with (A) doxorubicin or (B) gemcitabine and were then analysed for the growth of resistant colonies from single cells. Cells were stained with crystal violet after 15 days. Colonies containing ≥50 cells were counted. Results are presented as a percentage of control colony formation (100%). *P<0.05, **P<0.01 and ***P<0.01 compared to control. ≠P<0.05, ≠≠P<0.01 and ≠≠≠P<0.01 compared to MPL, doxorubicin or gemcitabine alone.